Each year, 450,000 Canadian women become pregnant and, as a result of their participation in prenatal screening for Down syndrome, approximately 10,000 of them will have an amniocentesis (i.e. sampling of liquid surrounding the fetus) and of those, 315 will be found to carry a baby with Down syndrome and 70 normal pregnancies will be lost from complications of the procedure.
It has been discovered recently that, during pregnancy, there is fetal DNA in maternal blood in sufficient quantities to be analyzed and methods have been proposed to detect the presence of a fetus with Down syndrome using maternal blood. The introduction of genomic blood testing as proposed in the context of this project could lead to increased detection of Down syndrome, less invasive screening with 9,700 amniocenteses avoided each year in Canada, improving the peace of mind of pregnant women, and preventing the accidental loss of 70 normal fetuses, at a lower overall cost than current practice.
However, these methods still need to be validated before being appropriately introduced in routine care. This project proposes to carry out an independent study that will validate the performance and utility of these new genomic technologies for screening in pregnant women using maternal blood. The team of researchers will identify an evidence-based cost-effective approach for implementation of this new technology in the Canadian health care system. They will develop decision-making tools that will assist couples in making informed decisions, as well as educational tools for health care professionals, all integral components of the implementation of genomics-based non-invasive prenatal diagnosis.
The deliverables of this project will enable decision makers–pregnant women and their partner–to make informed choices pertaining to prenatal genetic screening and diagnosis, such as screening for Down syndrome, and to reduce the risk to pregnancies associated with amniocentesis.
Decision box: What are my options regarding prenatal screening tests? Next update: April 2018
Improving Decision Making about Genetic Testing in the Clinic: An Overview of Effective Knowledge Translation Interventions. Légaré, F, Robitaille, H, Gane, C, Hébert, J, Labrecque, M, & Rousseau, F. PloS one 11.3 (2016): e0150123.
Use of a patient decision aid for prenatal screening for Down syndrome: what do pregnant women say? Leiva Portocarrero ME, Anik M. C. Giguère, Johanie Lépine, Mirjam M. Garvelink, Hubert Robitaille, Agathe Delanoë, Isabelle Lévesque, Brenda J. Wilson, Rousseau F and Légaré F. BMC Pregnancy and Childbirth. 2017 17:90.
Role of health literacy and psychosocial factors on the intention to use a decision aids for the Down syndrome prenatal screening: A theory-based online survey. Delanoë A, Lépine J, Turcotte S., Leiva Portocarrero ME, Robitaille H, Giguère A, Wilson BJ, Witteman H, Lévesque I, Guillaumie L, Légaré F. Journal of Medical Internet Research. 2016 Oct 28;18(10):e283.
Health literacy in pregnant women facing prenatal screening may explain their intention to use a patient decision aid: a short report. Delanoë A, Lépine J, Leiva Portocarrero ME, Robitaille H, Turcotte S, Lévesque I, Wilson BJ, Giguère AM, Légaré F. BMC Res Notes. 2016 9:339.
What factors influence health professionals to use a decision aids for Down syndrome prenatal screening? Lépine J, Portocarrero MEL, Delanoë A, Robitaille H, Lévesque I, Rousseau F, Wilson BJ, Giguère AMC and Légaré F. BMC Pregnancy and Childbirth 2016 16: 262.
Decision aids that support decisions about prenatal testing for Down syndrome: an environmental scan. Leiva Portocarrero ME, Garvelink MM, Becerra Perez MM, Giguère A, Robitaille H, Wilson BJ, Rousseau F, Légaré F. BMC Med Inform Decis Mak. 2015 Sep 24;15:76. doi: 10.1186/s12911-015-0199-6.